Coeptis Therapeutics (COEPW) Stock Price, News & Analysis

Company Overview

Coeptis Therapeutics is a clinical‐stage biopharmaceutical company focused on developing novel therapies for neurodegenerative and neuroinflammatory disorders. The company’s proprietary platform is based on engineered analogs of small heat shock proteins designed to modulate cellular stress responses, reduce inflammation and protect neurons from degeneration. Coeptis’s lead program is being advanced in amyotrophic lateral sclerosis (ALS), with additional preclinical studies underway in conditions such as multiple sclerosis and other central nervous system diseases.

Using its heat shock protein analog technology, Coeptis seeks to address the underlying pathology of neurodegeneration rather than merely managing symptoms. The company has completed early‐stage clinical testing in healthy volunteers and is preparing for patient trials in ALS, where few effective treatments exist. In parallel, Coeptis continues to expand its pipeline via in‐house research and strategic collaborations to explore applications in other neurological and inflammatory indications.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Coeptis Therapeutics is led by an experienced team of drug development professionals with backgrounds in neuroscience, immunology and biopharmaceutical research. The company leverages academic partnerships and contract research organizations across North America to advance its programs toward regulatory milestones and eventual commercialization.

Key Stats

• Today's Range: $0.0104 to $0.0104
• 50-Day Range: $0.0092 to $0.0192
• 52-Week Range: $0.01 to $0.05
• Volume: N/A
• Average Volume: 116,501 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: Software
• Sub-Industry: Application Software
• Current Symbol: NASDAQ:COEPW
• CIK: 1759186
• Web: coeptispharma.com
• Phone: 724 934 6467
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.36 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A